Cargando…

An overview on the treatments and prevention against COVID-19

BACKGROUND: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While COVID-19 is asymptomatic in most individuals, it can cause symptoms like pneumonia, ARDS (acute respiratory distress syndrome), and deat...

Descripción completa

Detalles Bibliográficos
Autores principales: Panahi, Yunes, Gorabi, Armita Mahdavi, Talaei, Sona, Beiraghdar, Fatemeh, Akbarzadeh, Abolfazl, Tarhriz, Vahideh, Mellatyar, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906607/
https://www.ncbi.nlm.nih.gov/pubmed/36755327
http://dx.doi.org/10.1186/s12985-023-01973-9
_version_ 1784884015976677376
author Panahi, Yunes
Gorabi, Armita Mahdavi
Talaei, Sona
Beiraghdar, Fatemeh
Akbarzadeh, Abolfazl
Tarhriz, Vahideh
Mellatyar, Hassan
author_facet Panahi, Yunes
Gorabi, Armita Mahdavi
Talaei, Sona
Beiraghdar, Fatemeh
Akbarzadeh, Abolfazl
Tarhriz, Vahideh
Mellatyar, Hassan
author_sort Panahi, Yunes
collection PubMed
description BACKGROUND: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While COVID-19 is asymptomatic in most individuals, it can cause symptoms like pneumonia, ARDS (acute respiratory distress syndrome), and death in others. Although humans are currently being vaccinated with several COVID-19 candidate vaccines in many countries, however, the world still is relying on hygiene measures, social distancing, and approved drugs. RESULT: There are many potential therapeutic agents to pharmacologically fight COVID-19: antiviral molecules, recombinant soluble angiotensin-converting enzyme 2 (ACE2), monoclonal antibodies, vaccines, corticosteroids, interferon therapies, and herbal agents. By an understanding of the SARS-CoV-2 structure and its infection mechanisms, several vaccine candidates are under development and some are currently in various phases of clinical trials. CONCLUSION: This review describes potential therapeutic agents, including antiviral agents, biologic agents, anti-inflammatory agents, and herbal agents in the treatment of COVID-19 patients. In addition to reviewing the vaccine candidates that entered phases 4, 3, and 2/3 clinical trials, this review also discusses the various platforms that are used to develop the vaccine COVID-19.
format Online
Article
Text
id pubmed-9906607
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99066072023-02-08 An overview on the treatments and prevention against COVID-19 Panahi, Yunes Gorabi, Armita Mahdavi Talaei, Sona Beiraghdar, Fatemeh Akbarzadeh, Abolfazl Tarhriz, Vahideh Mellatyar, Hassan Virol J Research BACKGROUND: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While COVID-19 is asymptomatic in most individuals, it can cause symptoms like pneumonia, ARDS (acute respiratory distress syndrome), and death in others. Although humans are currently being vaccinated with several COVID-19 candidate vaccines in many countries, however, the world still is relying on hygiene measures, social distancing, and approved drugs. RESULT: There are many potential therapeutic agents to pharmacologically fight COVID-19: antiviral molecules, recombinant soluble angiotensin-converting enzyme 2 (ACE2), monoclonal antibodies, vaccines, corticosteroids, interferon therapies, and herbal agents. By an understanding of the SARS-CoV-2 structure and its infection mechanisms, several vaccine candidates are under development and some are currently in various phases of clinical trials. CONCLUSION: This review describes potential therapeutic agents, including antiviral agents, biologic agents, anti-inflammatory agents, and herbal agents in the treatment of COVID-19 patients. In addition to reviewing the vaccine candidates that entered phases 4, 3, and 2/3 clinical trials, this review also discusses the various platforms that are used to develop the vaccine COVID-19. BioMed Central 2023-02-08 /pmc/articles/PMC9906607/ /pubmed/36755327 http://dx.doi.org/10.1186/s12985-023-01973-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Panahi, Yunes
Gorabi, Armita Mahdavi
Talaei, Sona
Beiraghdar, Fatemeh
Akbarzadeh, Abolfazl
Tarhriz, Vahideh
Mellatyar, Hassan
An overview on the treatments and prevention against COVID-19
title An overview on the treatments and prevention against COVID-19
title_full An overview on the treatments and prevention against COVID-19
title_fullStr An overview on the treatments and prevention against COVID-19
title_full_unstemmed An overview on the treatments and prevention against COVID-19
title_short An overview on the treatments and prevention against COVID-19
title_sort overview on the treatments and prevention against covid-19
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906607/
https://www.ncbi.nlm.nih.gov/pubmed/36755327
http://dx.doi.org/10.1186/s12985-023-01973-9
work_keys_str_mv AT panahiyunes anoverviewonthetreatmentsandpreventionagainstcovid19
AT gorabiarmitamahdavi anoverviewonthetreatmentsandpreventionagainstcovid19
AT talaeisona anoverviewonthetreatmentsandpreventionagainstcovid19
AT beiraghdarfatemeh anoverviewonthetreatmentsandpreventionagainstcovid19
AT akbarzadehabolfazl anoverviewonthetreatmentsandpreventionagainstcovid19
AT tarhrizvahideh anoverviewonthetreatmentsandpreventionagainstcovid19
AT mellatyarhassan anoverviewonthetreatmentsandpreventionagainstcovid19
AT panahiyunes overviewonthetreatmentsandpreventionagainstcovid19
AT gorabiarmitamahdavi overviewonthetreatmentsandpreventionagainstcovid19
AT talaeisona overviewonthetreatmentsandpreventionagainstcovid19
AT beiraghdarfatemeh overviewonthetreatmentsandpreventionagainstcovid19
AT akbarzadehabolfazl overviewonthetreatmentsandpreventionagainstcovid19
AT tarhrizvahideh overviewonthetreatmentsandpreventionagainstcovid19
AT mellatyarhassan overviewonthetreatmentsandpreventionagainstcovid19